Revenue remains highly volatile and decoupled from commercial scale, with 2026Q1 revenue of $113.8K failing to cover SG&A expenses that frequently exceed $2M per quarter.
| Sales/Revenue | 1.41M | 1.36M | 0 | 0 | 0 | 75K | 30.76K | 0 | 0 | 0 |
| Revenue Growth % | 2148.85% | - | - | - | -100% | 143.82% | - | - | - | - |
| Cost of Goods Sold | 180.63K | 180.63K | 0 | 0 | 0 | 0 | 964.22K | 0 | 0 | 0 |
| COGS % of Revenue | - | 13.25% | - | - | - | - | 3134.54% | - | - | - |
| Gross Profit | 1.23M | 1.18M | 0 | 0 | 0 | 75K | -933.46K | 0 | 0 | 0 |
| Gross Margin % | 87.23% | 86.75% | - | - | - | 100% | -3034.54% | - | - | - |
| Gross Profit Growth % | - | - | - | - | -100% | 108.03% | - | - | - | - |
| Operating Expenses | 14.13M | 14.23M | 10.05M | 21.49M | 34.2M | 14.12M | 5.93M | 0 | 308.31K | 10.08K |
| OpEx % of Revenue | - | 1043.69% | - | - | - | 18827.91% | 19270.98% | - | - | - |
| Selling, General & Admin | 8.86M | 11.95M | 6.72M | 13.82M | 34.18M | 14.12M | 5.78M | 0 | 308.31K | 10.08K |
| SG&A % of Revenue | - | 876.62% | - | - | - | 18827.91% | 18777.71% | - | - | - |
| Research & Development | 1.43M | 1.28M | 2.33M | 6.67M | 20.89K | 0 | 3.54K | 0 | 0 | 0 |
| R&D % of Revenue | - | 93.7% | - | - | - | - | 11.52% | - | - | - |
| Other Operating Expenses | 1.75M | 1M | 1M | 1M | 0 | 0 | 148.19K | 0 | 0 | 0 |
| Operating Income | -12.9M | -13.04M | -10.05M | -21.49M | -34.2M | -14.05M | -6.86M | 0 | -308K | -10.08K |
| Operating Margin % | -912.42% | -956.94% | - | - | - | -18727.91% | -22305.53% | - | - | - |
| Operating Income Growth % | - | -29.73% | 53.22% | 37.15% | -143.46% | -104.71% | - | 100% | -2956.47% | - |
| EBITDA | -11.73M | -11.82M | -9.02M | -20.46M | -33.19M | -13.6M | -6.54M | 171.86K | -344K | 2.65M |
| EBITDA Margin % | -829.87% | -867.24% | - | - | - | -18131.36% | -21254.1% | - | - | - |
| EBITDA Growth % | -16.23% | -31.11% | 55.92% | 38.38% | -144.1% | -107.99% | -3904.24% | 149.96% | -112.99% | - |
| D&A (Non-Cash Add-back) | 1.17M | 1.22M | 1.04M | 1.04M | 1M | 447.41K | 323.43K | 171.86K | -36K | 2.66M |
| EBIT | -12.04M | -11.63M | -10.42M | -21.16M | -37.36M | -13.26M | -9.01M | 0 | -308K | -10.08K |
| Net Interest Income | -459.65K | -525.88K | -396.12K | -107.69K | -218.41K | -187K | -148K | 0 | 0 | 0 |
| Interest Income | 116.5K | 116.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 576.14K | 642.38K | 396.12K | 107.69K | 218.41K | 187.13K | 148.19K | 0 | 0 | 0 |
| Other Income/Expense | 24.01K | 766.31K | -822.92K | 224.59K | -3.38M | 596.65K | -2.29M | -2.23K | 0 | 2.66M |
| Pretax Income | -12.88M | -12.28M | -10.88M | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K | 0 | 2.65M |
| Pretax Margin % | -910.73% | -900.72% | - | - | - | -17932.37% | -29765.89% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - | 0% |
| Net Income | -11.87M | -11.92M | -10.68M | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K | -344K | 2.65M |
| Net Margin % | -839.69% | -874.29% | - | - | - | -17932.37% | -29765.89% | - | - | - |
| Net Income Growth % | -21.48% | -11.58% | 49.78% | 43.4% | -179.38% | -46.89% | -409760.61% | 99.35% | -112.99% | - |
| Net Income (Continuing) | -12.88M | -12.28M | -10.88M | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K | -344K | 2.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 401.88K | 506.16K | 682.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.97 | -2.81 | -5.65 | -0.83 | -2.87 | -13.16 | -0.45 | -0.00 | -184.81 | 1421.16 |
| EPS Growth % | -183.07% | 50.27% | -580.72% | 71.08% | 78.19% | -2824.44% | - | 100% | -113% | - |
| EPS (Basic) | - | -2.81 | -5.65 | -0.83 | -2.87 | -13.16 | -0.45 | -0.00 | -184.81 | 1421.16 |
| Diluted Shares Outstanding | 6.03M | 4.23M | 1.93M | 25.69M | 14.3M | 1.02M | 20.44M | 10.78M | 1.86K | 1.86K |
| Basic Shares Outstanding | 6.03M | 4.23M | 1.93M | 25.69M | 14.3M | 1.02M | 20.44M | 10.78M | 1.86K | 1.86K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Insufficient cash runway
As indicated by recent financial disclosures, Coeptis Therapeutics generated $113.8K in revenue during 2026Q1, reflecting a highly sporadic, non-recurring income stream that remains decoupled from any sustainable product-driven growth trajectory typical of established biotechnology firms within the broader healthcare sector.
The revenue profile appears to be entirely dependent on milestone payments or licensing activities rather than consistent commercial sales. This reliance on transactional inflows suggests that top-line growth is currently a function of R&D progress rather than market adoption, making future revenue visibility highly speculative.
Based on reported quarterly filings, the company's SG&A expenses frequently exceed $2M per period, which, when combined with R&D spending, creates a cost structure that significantly dwarfs the company's limited revenue generation and necessitates constant external capital support.
The persistent level of SG&A spending relative to the company's pre-commercial status suggests a high fixed-cost burden that may be difficult to scale down without compromising pipeline development. Investors should monitor whether these expenditures are yielding tangible clinical milestones or merely sustaining administrative operations.
According to historical income statements, the company's net income is frequently distorted by non-cash items, including significant stock-based compensation and warrant-related valuation adjustments, which complicate the assessment of the firm's true underlying operational performance and cash burn rate.
The presence of large, fluctuating stock-based compensation figures suggests that equity-linked incentives are a primary tool for managing cash outflows. This practice may mask the true economic cost of talent acquisition and development, warranting a cautious interpretation of reported bottom-line figures.
As highlighted in recent SEC filings, the company's cash position of approximately $5.67M appears insufficient to sustain its current quarterly operating losses, suggesting that the firm faces an imminent risk of dilutive financing or restrictive debt arrangements to maintain its clinical pipeline.
The disparity between the current cash balance and the ongoing burn rate indicates that the company's survival is contingent upon either immediate capital raises or the successful achievement of licensing milestones. This financial fragility poses a significant risk to equity holders, as the need for liquidity may override long-term value creation.
Quick answers to the most common questions about buying COEPW stock.
For fiscal year 2025, Coeptis Therapeutics Holdings, Inc. (COEPW) reported total revenue of $1.4M.
Coeptis Therapeutics Holdings, Inc. (COEPW) reported a net loss of $11.9M for the fiscal year ending 2025.
Coeptis Therapeutics Holdings, Inc. (COEPW) reported an operating income of $-13.0M, resulting in an operating profit margin of -956.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Coeptis Therapeutics Holdings, Inc. (COEPW) generated $1.2M in gross profit for the year, representing a gross profit margin of 86.7%. This demonstrates the company's core pricing power and production efficiency.